Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 3, 2006, Pages 321-327

  Bergman, Arthur J ^a   Burke, Joanne ^a   Larson, Patrick ^a   Johnson Levonas, Amy O ^a   Reyderman, Larisa ^a   Statkevich, Paul ^a   Kosoglou, Teddy ^a   Greenberg, Howard E ^b   Kraft, Walter K ^b   Frick, Glenn ^b   Murphy, Gail ^a   Gottesdiener, Keith ^a   Paolini, John F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cyclosporine; Ezetimibe; Interaction

Indexed keywords

CYCLOSPORIN A; EZETIMIBE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GEOMETRY; HEADACHE; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZETIDINES; CROSS-OVER STUDIES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 32944463058     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005284851     Document Type: Article

References (32)

1. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997 ; 63: 331-338.
2. Brunner FP, Fassbinder W, Broyer M, et al. Survival on renal replacement therapy: data fromtheEDTARegistry. Nephrol Dial Transplant. 1988 ; 3: 109-122.
3. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995 ; 60: 451-457.
4. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996 ; 7: 158-165.
5. Kobashigawa JA. Statins and cardiac allograft vasculopathy after heart transplantation. Semin Vasc Med. 2004 ; 4: 401-406.
6. Ballantyne CM, el Masri B, Morrisett JD, Torre-Amione G. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Curr Opin Cardiol. 1997 ; 12: 153-160.
7. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002 ; 346: 580-590.
8. Aranda JM, Jr, Hill J. Cardiac transplant vasculopathy. Chest. 2000 ; 118: 1792-1800.
9. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in renal transplant recipients treated with cyclosporine. Transplant Proc. 1989 ; 21: 3670-3673.
10. Isoniemi H. Hyperlipidemia after renal transplantation - facts and potential implications. Nephrol Dial Transplant. 1995 ; 10: 457-459.
11. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991 ; 18: 353-358.
12. Raine AE, Carter R, Mann JI, Morris PJ. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant. 1988 ; 3: 458-463.
13. Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994 ; 57: 1479-1483.
14. Holdaas H, Fellstrom B, Jardine AG, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005 ; 20: 974-980.
15. Lentine KL, Brennan DC. Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol Dial Transplant. 2004 ; 19: 2378-2386.
16. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92: 152-160.
17. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs. 2003 ; 63: 367-378.
18. Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther. 2002 ; 40: 439-450.
19. Davidson MH. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep. 2000 ; 2: 14-19.
20. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003 ; 24: 729-741.
21. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002 ; 90: 1084-1091.
22. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005 ; 44: 467-494.
23. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo [abstract]. Clin Pharmacol Ther. 2000 ; 67: 152-152.
24. Bergman A, Johnson-Levonas A, Burke J, et al. Assessment of pharmacokinetic interaction between ezetimibe and cyclosporine [abstract]. Clin Pharmacol Ther. 2005 ; 77: 75-75.
25. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 ; 118: 1841-1847.
26. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human Pglycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 ; 268: 6077-6080.
27. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001 ; 69: 14-23.
28. Kolars JC, Awni WM, Merion RM, Watkins PB. First-passmetabolism of cyclosporin by the gut. Lancet. 1991 ; 338: 1488-1490.
29. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos. 1989 ; 17: 197-207.
30. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996 ; 30: 141-179.
31. Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002 ; 53: 75-82.
32. Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant. 2001 ; 16: 373-377.